https://webnewsinsider.com/nih-study-links-forever-chemicals-to-aggressive-breast-cancer-rates/ WebNewsInsider en 2026-11-11T15:28:27+08:00 NIH Study Links Forever Chemicals to Aggressive Breast Cancer Rates https://webnewsinsider.com/experimental-drug-combo-doubles-one-year-survival-rates-in-pancreatic-cancer-trial/ WebNewsInsider en 2026-11-11T01:12:13+08:00 Experimental Drug Combo Doubles One-Year Survival Rates in Pancreatic Cancer Trial https://webnewsinsider.com/why-achieve-says-most-americans-feel-their-financial-stability-is-slipping-away/ WebNewsInsider en 2026-11-10T23:25:04+08:00 Why Achieve Says Most Americans Feel Their Financial Stability is Slipping Away https://webnewsinsider.com/locking-in-high-yields-how-current-cd-rates-offer-safe-returns-amid-shifting-economic-outlooks/ WebNewsInsider en 2026-11-10T23:23:17+08:00 Locking In High Yields: How Current CD Rates Offer Safe Returns Amid Shifting Economic Outlooks https://webnewsinsider.com/factor-xia-inhibitor-asundexian-cuts-recurrent-stroke-risk-without-raising-major-bleeding/ WebNewsInsider en 2026-11-10T09:11:30+08:00 Factor XIa Inhibitor Asundexian Cuts Recurrent Stroke Risk Without Raising Major Bleeding https://webnewsinsider.com/ucsf-scientists-eliminate-deadly-brain-tumors-in-mice-with-b-sync-therapy/ WebNewsInsider en 2026-11-10T07:21:34+08:00 UCSF Scientists Eliminate Deadly Brain Tumors in Mice with B-SYNC Therapy https://webnewsinsider.com/medicare-denies-949-multi-cancer-blood-test-leaving-seniors-with-full-bill-until-2029/ WebNewsInsider en 2026-11-10T06:21:03+08:00 Medicare Denies $949 Multi-Cancer Blood Test, Leaving Seniors With Full Bill Until 2029 https://webnewsinsider.com/indias-nppa-slashes-137-cancer-drug-prices-by-up-to-96-saving-%e2%82%b93500-crore-annually/ WebNewsInsider en 2026-11-10T02:14:35+08:00 India’s NPPA slashes 137 cancer drug prices by up to 96%, saving ₹3,500 crore annually https://webnewsinsider.com/fda-orders-class-wide-glp-1-label-update-for-rare-eye-disease-risk/ WebNewsInsider en 2026-11-10T00:21:16+08:00 FDA orders class-wide GLP-1 label update for rare eye disease risk https://webnewsinsider.com/why-oncology-trials-chase-surrogate-endpoints-the-fda-ignores/ WebNewsInsider en 2026-11-09T23:22:29+08:00 Why Oncology Trials Chase Surrogate Endpoints the FDA Ignores